Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan in Pulmonary Arterial Hypertension (SR-PAAS Study 1)
NCT00795639Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of sitaxsentan in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Dec 2008; status: terminated.
02
Drugs
sitaxsentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00795639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795639.